MRK - Merck & Co., Inc.

NYSE - NYSE Delayed Price. Currency in USD
81.17
+0.15 (+0.19%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close81.02
Open81.30
Bid81.02 x 800
Ask81.62 x 3200
Day's Range81.12 - 81.94
52 Week Range58.03 - 83.85
Volume4,862,195
Avg. Volume10,390,265
Market Cap208.984B
Beta (3Y Monthly)0.31
PE Ratio (TTM)25.63
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.20 (2.80%)
Ex-Dividend Date2019-03-14
1y Target EstN/A
  • Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary
    Zacks23 hours ago

    Nektar (NKTR) Announces Formation of CNS-Focused Subsidiary

    Nektar (NKTR) forms wholly-owned subsidiary, Inheris Biopharm, focusing on CNS pipeline. The subsidiary will mainly be responsible for potential commercialization of under review pain drug, NKTR-181.

  • Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates
    Zacks23 hours ago

    Pharma Stock Roundup: MRK's Cancer Biotech Buyout, ABBV, LLY's Pipeline Updates

    Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.

  • Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics
    Zacksyesterday

    Dow 30 Stock Roundup: Home Depot Earnings Impress, Merck to Buy Peloton Therapeutics

    The index suffered a difficult week as investors braced for a protracted U.S.-China trade war.

  • Synlogic (SYBX) Enters Cancer Collaboration with Roche
    Zacks2 days ago

    Synlogic (SYBX) Enters Cancer Collaboration with Roche

    Synlogic (SYBX) announces clinical collaboration with Roche to develop its pre-clinical cancer candidate in combination with Roche's PD-L1 inhibitor, Tecentriq.

  • J&J's Invokana sNDA Gets Priority Review Status From FDA
    Zacks2 days ago

    J&J's Invokana sNDA Gets Priority Review Status From FDA

    FDA grants priority review to J&J's (JNJ) Invokana sNDA for the treatment of chronic kidney disease in patients with type II diabetes

  • Array BioPharma Gains on Colorectal Cancer Study Success
    Zacks3 days ago

    Array BioPharma Gains on Colorectal Cancer Study Success

    Array BioPharma's (ARRY) phase III study, evaluating the Braftovi triplet for treating metastatic colorectal cancer, meets the primary goal of ORR and OS. Shares rally.

  • Benzinga3 days ago

    Merck's Keytruda Vs. Bristol-Myers Squibb's Opdivo In Q1 And Beyond

    Two big pharma titans are battling for supremacy in the field of oncology immunotherapy. From the looks of it, Kenilworth, New Jersey-based Merck & Co., Inc. (NYSE: MRK) may have the upper hand over Bristol-Myers Squibb Co (NYSE: BMY). Before poring over the specifics, here's what immunotherapy means: it's a type of cancer treatment that uses the body's immune system to put up a fight against cancer cells.

  • Company News For May 22, 2019
    Zacks3 days ago

    Company News For May 22, 2019

    Companies In The News Are: KSS,AZO,HD,MRK

  • Merck to Buy Private Cancer Drugmaker Peloton Therapeutics
    Zacks3 days ago

    Merck to Buy Private Cancer Drugmaker Peloton Therapeutics

    Merck (MRK) signs a definitive agreement to buy small private biotech, Peloton Therapeutics for $1.05 billion in cash to boost its oncology pipeline.

  • Barrons.com4 days ago

    Merck Snaps Up Cancer Drugmaker Peloton Therapeutics

    American pharmaceutical giant Merck & Co. said it is buying Peloton Therapeutics, a clinical-stage biopharmaceutical company, for $1.05 billion in cash.

  • These 3 Major Drug Manufacturers Are Strong Performers
    GuruFocus.com4 days ago

    These 3 Major Drug Manufacturers Are Strong Performers

    Roche Holding AG (RHHBY) has climbed 2.4% over the last week, 0.5% over the past month, 5.7% so far this year, 17.6% over the last 52 weeks and 5.3% over the past three years through May 20. Warning! GuruFocus has detected 3 Warning Signs with RHHBY. Currently, the company is paying an annual dividend of $1.07 per common share, which, based on the closing share price on May 20, leads to a forward dividend yield of 3.27% versus the industry median of 1.66%.

  • After filing an IPO, Dallas company to sell to Merck for $1.05 billion
    American City Business Journals4 days ago

    After filing an IPO, Dallas company to sell to Merck for $1.05 billion

    DFW company, had filed to go public less than a month ago, could see shareholders get additional $1.15 billion

  • Merck buys Peloton to expand its kidney cancer treatment portfolio
    Reuters4 days ago

    Merck buys Peloton to expand its kidney cancer treatment portfolio

    The acquisition can strengthen Merck's presence in the field of renal cell carcinoma and bolster its cancer drug portfolio. Merck's blockbuster immunotherapy Keytruda was approved last month in the United States for treating renal cell cancer.

  • Bloomberg4 days ago

    Merck to Buy Peloton for Up to $2.2 Billion, Day Before IPO

    Merck will pay $1.05 billion in cash, plus $1.15 billion in additional payments based on how the small company’s experimental drugs fare as they are developed further by Merck, the firms said in a statement announcing the deal Tuesday. The deal offers an immediate payout for Peloton’s investors, including Dallas-based venture capital firm Remeditex Ventures and San Francisco’s The Column Group. At the $17 high range of Peloton’s expected initial public offering, the market would have valued the company at $756 million.

  • Benzinga4 days ago

    Merck To Buy Clinical-Stage Biopharma Peloton Therapeutics For More Than $1B

    Merck & Co., Inc.  (NYSE: MRK ) announced an agreement Tuesday to acquire the clinical-stage biopharmaceutical company Peloton Therapeutics for $1.05 billion cash upfront and a further $1.15 billion in ...

  • TheStreet.com4 days ago

    Merck to Acquire Peloton Therapeutics for About $1B in Cash

    on Tuesday said it agreed to buy privately held Peloton Therapeutics for about $1 billion in cash, giving it access to Peloton's molecular therapy biotech treatments currently in development for patients with cancer and other non-oncology diseases. Under terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of Peloton in exchange for an upfront payment of $1.05 billion in cash, the company said. Peloton shareholders also will be eligible to receive a further $1.15 billion contingent upon successful achievement of future regulatory and sales milestones for certain candidates.

  • Merck to buy cancer drug developer in deal that could be worth more than $2B
    American City Business Journals4 days ago

    Merck to buy cancer drug developer in deal that could be worth more than $2B

    Merck's deal for Dallas-based Peloton Therapeutics includes an upfront payment of $1.05 billion.

  • Merck's Keytruda Fails in Late-Stage Breast Cancer Study
    Zacks4 days ago

    Merck's Keytruda Fails in Late-Stage Breast Cancer Study

    Merck's (MRK) Keytruda fails in a late-stage study evaluating it as second- or third-line treatment for breast cancer.

  • MarketWatch4 days ago

    Merck to acquire Peloton Therapeutics for upfront payment of $1.05 billion in cash

    Merck & Co. Inc. said Tuesday it has reached an agreement to acquire Peloton Therapeutics Inc. for an upfront payment of $1.05 billion in cash. Peloton, a clinical-stage biotech focused on cancer treatments, was expected to price an initial public offering on Wednesday. The biotech's business hinges instead on two drugs that are designed to block a transcription factor called hypoxia-inducible factor-2 alphaαthat - among other things - regulates how the body responds to low oxygen levels. Under the terms of the deal, Peloton shareholders will be entitled to a further $1.15 billion in milestone payments based on the achievement of certain future regulatory and sales goals. "This acquisition exemplifies Merck's strategy to pursue novel therapeutic candidates based on exceptionally promising and innovative research," said Dr. Roger M. Perlmutter, president of Merck Research Laboratories. "Peloton scientists have applied their unique expertise in HIF-2α biology to develop PT2977, which has already shown intriguing activity in the treatment of renal cell carcinoma. We look forward to advancing this late-stage asset as part of our broad oncology R&D program." The deal is expected to close in the third quarter. Merck shares were not active premarket, bu have gained 34.7% in the last 12 months, while the S&P 500 has gained 3.9%.

  • Investing.com4 days ago

    Stocks - Kohls, JC Penny, Tesla Fall Premarket; Boeing Rises

    Investing.com - Stocks in focus in premarket trading on Tuesday:

  • CNBC5 days ago

    Stocks making the biggest moves after hours: GM, Snap, Merck and more

    Shares of Merck & Co MRK dropped as much as 9% in extended trading on Monday, before erasing those losses, after the pharmaceutical company announced that its medication Keytruda failed to meet expectations in phase 3 of the drug's trial. Shares of Snap SNAP ticked slightly higher after the company announced it has named a new chief financial officer to take over for interim CFO Lara Sweet, effective immediately. The social media company promoted Derek Andersen, Snap's current vice president of finance, to permanently fill the position of chief financial officer.

  • Reuters5 days ago

    Merck's Keytruda fails as monotherapy in breast cancer study

    Merck & Co Inc said on Monday its blockbuster cancer drug Keytruda failed to meet the main goal of a late-stage study testing the drug as a standalone treatment in patients with an aggressive type of breast cancer. Keytruda, among a class of medicines called PD-1 inhibitors, did not meet the main goal of helping patients live longer, when compared to chemotherapy. The treatment will continue to be studied in earlier stages of the disease and in combination with chemotherapy in patients with triple negative breast cancer, the company said.

  • MarketWatch5 days ago

    Merck shares slip as Keytruda fails another clinical trial

    Merck & Co. shares slipped in the extended session Monday after the drug maker said its cancer treatment Keytruda failed to meet clinical endpoints in another late-stage study. Merck shares declined 0.7% after hours, following a 0.2% rise to close the regular session at $78.88. In a Phase 3 clinical study, Merck said Keytruda "did not meet its pre-specified primary endpoint of superior overall survival" compared with chemotherapy in a subset of breast cancer patients. In late April, Merck said Keytruda did not show significant improvement over chemotherapy in gastric cancer patients. For the year, Merck shares are up 3.2%, compared with a 13.3% rise in the S&P 500 index .

  • Reuters5 days ago

    U.S. Supreme Court gives Merck another shot to avoid Fosamax lawsuits

    The U.S. Supreme Court on Monday gave Merck & Co a new opportunity to avoid lawsuits accusing the company of failing to properly warn patients of debilitating thigh-bone fractures from taking its osteoporosis drug Fosamax, throwing out a lower court decision that had revived the litigation. The nine justices unanimously directed the Philadelphia-based 3rd U.S. Circuit Court of Appeals to reconsider its decision to let the lawsuits proceed even though the Food and Drug Administration had rebuffed Merck when the company sought to add a warning to Fosamax's label about fracture risk.